01558 HEC CJ PHARM
- 12.800
- 0.0000.00%
HEC CJ PHARM News
東陽光長江藥業：年度報告 2023
Changes in Hong Kong stocks | Dongyangguang Changjiang Pharmaceutical (01558) is now up more than 3%, and the procurement price of insulin is more moderate. The company plans to win the bid for 5 products
Dongyangguang Changjiang Pharmaceutical (01558) is now up more than 3%. As of press release, it is up 3.15% to HK$12.46, with a turnover of HK$18.895 million.
Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger With Sunshine Lake Pharma
Yichang Hec Changjiang Pharmaceutical Co (HKG:1558) and Sunshine Lake Pharma jointly said that they are looking into the possibilities of a merger, according to a Monday Hong Kong bourse. A definitive
Dongyangguang Changjiang Pharmaceutical (01558): The potential offender has not proposed a clear plan for the possible merger to the company
Dongyangguang Changjiang Pharmaceutical (01558) issued an announcement. Guangdong Dongyangyang Pharmaceutical Co., Ltd. (potential offender) announced...
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps
Yichang Hec Changjiang Pharmaceutical's (HKG:1558) net profit attributable to equity holders surged to 1.99 billion yuan in 2023 from 76.6 million yuan in 2022, according to a filing made with the Hon
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023
YiChang HEC ChangJiang Pharmaceutical Co's (HKG:1558) net profit attributable to shareholders rose 2,501% to 2 billion yuan in the year ended Dec. 31, 2023, from 77 million yuan a year ago, according
HEC CJ PHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Dongyangguang Changjiang Pharmaceutical (01558.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 18, 丨 Dongyangguang Changjiang Pharmaceutical (01558.HK) announced that the board of directors meeting will be held on March 28, 2024 (Thursday) to review and approve the annual results and publication of the company and its subsidiaries for the year ended 31 December 2023, and to consider payment of a final dividend (if any).
HEC CJ PHARM: NOTICE OF BOARD MEETING
HEC CJ PHARM: SUPPLEMENTAL ANNOUNCEMENT POSITIVE PROFIT ALERT
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023
Yichang Hec Changjiang Pharmaceutical (HKG:1558) expects to record a net profit attributable to the parent company between 1.9 billion yuan and 2.1 billion yuan for the year ended Dec. 31, 2023, up by
Changes in Hong Kong stocks | Dongyangguang Changjiang Pharmaceutical (01558) rose more than 8% after profit, expected to increase annual net profit by 23 to 26 times, and the parent company is considering absorbing and merging companies
Dongyangguang Changjiang Pharmaceutical (01558) rose more than 8% after profit. As of press release, it rose 7.51% to HK$10.7, with a turnover of HK$711 million.
YiChang HEC ChangJiang Pharmaceutical Expects 2023 Revenue at CNY6.30B Vs CNY3.75B Year Ago
YiChang HEC ChangJiang Pharmaceutical Expects 2023 Revenue at CNY6.30B Vs CNY3.75B Year Ago
GLONGHUI ANNOUNCEMENT SELECTION (HK Stock) | BOSS Direct Employment - W (02076.HK) Announces Annual Results Adjusted Net Profit Reaches 2.156 Billion Yuan; Total Revenue for the First Quarter Is Expected to Increase by 28.3% to 30.7%
[Today's Focus] BOSS Direct Employment-W (02076.HK) announces annual results with adjusted net profit of 2.56 billion yuan. Total revenue for the first quarter is expected to increase 28.3% to 30.7% BOSS Direct Employment-W (02076.HK) announced that revenue for the fourth quarter of 2023 was RMB 1,580.2 million, an increase of 46.0% over RMB 1,082.3 million in the same period of 2022. Revenue for the full year of 2023 was RMB 5,952.0 million, up 31 from RMB 4,511.1 million for the full year of 2022.
Dongyangguang Changjiang Pharmaceutical (01558.HK) Yingxi: Expected net profit of 1.90 billion yuan to mother in 2023 to 210 billion yuan
Gelonghui, March 12, 丨 Dongyangguang Changjiang Pharmaceutical (01558.HK) announced, based on the unaudited management accounts currently available to the Group and preliminary estimates of the company's management, the main financial data is as follows: 1. For the year ended December 31, 2023, the Group expects to record a turnover of approximately RMB 6.295 billion, an increase of about 68.09% over the same period last year; 2. For the year ended December 31, 2023, the Group expects to record profit before tax of approximately RMB 2,027 billion to RMB 2,027 billion 2,227 billion yuan, compared with last year
HEC CJ PHARM: ANNOUNCEMENT POSITIVE PROFIT ALERT
Changes in Hong Kong stocks | Dongyangguang Changjiang Pharmaceutical (01558) resumed trading and opened more than 6%. Guangdong Dongyangguang Pharmaceutical is considering absorbing and merging companies through a share exchange
Dongyangguang Changjiang Pharmaceutical (01558) resumed trading more than 6%. As of press release, it rose 6.58% to HK$11.98, with a turnover of HK$3.3832 million.
Dongyangguang Changjiang Pharmaceutical (01558.HK) resumed trading this morning
Gelonghui March 11 丨 Dongyangguang Changjiang Pharmaceutical (01558.HK) announced that the company's H shares will resume trading at 9:00 a.m. today (11/3/2024).
Dongyangguang Changjiang Pharmaceutical (01558.HK): Guangdong Dongyangyang Pharmaceutical is considering absorbing the merged company through a share exchange and resuming trading on the 11th
Gelonghui March 8, 丨 Dongyangguang Changjiang Pharmaceutical (01558.HK) announced that its parent company Guangdong Dongyangyang Pharmaceutical Co., Ltd. was notified that the latter and its wholly-owned subsidiary Hong Kong Dongyangyang Sales Co., Ltd. (the company's direct shareholder, holds 226 million H shares, which is equivalent to about 25.71% of the company's total issued share capital) entered into a share transfer agreement on March 8, 2024. According to this, Hong Kong Dongyangyang will transfer sales shares to Guangdong Dongyangyang Pharmaceutical in accordance with the terms and conditions of the agreement, at a consideration of HK$9.14 per share. The total consideration for share transfers was HK$2,067 billion
Why Investors Shouldn't Be Surprised By YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 37% Share Price Surge
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) shares have had a really impressive month, gaining 37% after a shaky period beforehand. The last 30 days bring the annual gain to a very s
Analysis
Price Target
No Data
